Study of Monitoring Exhaled NO in Symptomatic Asthmatic Adults and Children During Anti-inflammatory Treatment (eNOugh)

This study has been completed.
Sponsor:
Information provided by:
Aerocrine AB
ClinicalTrials.gov Identifier:
NCT00388570
First received: October 16, 2006
Last updated: November 3, 2011
Last verified: November 2011

October 16, 2006
November 3, 2011
October 2006
June 2007   (final data collection date for primary outcome measure)
  • The primary analysis variable will be the percent change in FENO measured with
  • NIOX MINO® and NIOX® between Visit 1 to Visit 2.
Not Provided
Complete list of historical versions of study NCT00388570 on ClinicalTrials.gov Archive Site
  • Agreement between NIOX MINO® and NIOX® will be assessed by comparing
  • individual pair-wise FENO measurements from visit V1.
  • The change in FENO measured with NIOX MINO following corticosteroid therapy
  • in asthma will be compared with improvements in standard asthma outcome
  • measures (asthma symptoms and spirometry).
  • To investigate the inter-operator variability FENO measurements with
  • NIOX MINO in the same subject when different operators take FENO measurements. Three operator each takes two completed measurements in the same subject in a point of care setting.
Not Provided
Not Provided
Not Provided
 
Study of Monitoring Exhaled NO in Symptomatic Asthmatic Adults and Children During Anti-inflammatory Treatment
A Multicenter, Device Randomized, Open-label Prospective Single-cohort Study of Monitoring Exhaled NO in Symptomatic Asthmatic Adults and Children During Anti-inflammatory Treatment

The purpose of this study is to demonstrate substantial equivalence between two medical devices which measure nitric oxide in exhaled breath, NIOX MINO® and NIOX® in Symptomatic Asthmatic Adults and Children.

Asthma is a chronic inflammatory disorder of the airways. Chronically inflamed airways are hyperresponsive; they become obstructed and airflow is limited (by bronchoconstriction, mucus plugs, and increased inflammation) when airways are exposed to various risk factors. Asthma causes recurring episodes of wheezing, breathlessness, chest tightness, and coughing particularly at night or in the early morning.

NO is an important endogenous regulatory molecule that is widely distributed throughout the body. The detection of NO in exhaled air was first reported in 1991, and, soon after it was shown that the levels NO in exhaled air are elevated in patients with asthma. There is now much evidence showing that measurement of the concentration of NO in exhaled air offers a useful non−invasive method of assessing inflammatory airway disease.

Exhaled NO is not increased during bronchospasm unless there is coexisting inflammation. Exhaled NO may have a valuable role in differentiating between the inflammatory and bronchospastic components of clinical asthma, and is also useful for guiding the therapeutic use of steroids and other anti−inflammatory agents.

A study on asthmatics and non−asthmatics subjects has shown that substantial equivalence exists between the stationary device NIOX® and the hand held device NIOX MINO® when comparing NO measurements, when similar conditions are considered and examinations are made as consistently as possible.

In a study with the stationary device NIOX®, exhaled NO was measured before and after two weeks of inhaled corticosteroid treatment in unstable steroid−naïve adult and paediatric asthmatic subjects. The result was a 50.5% mean reduction of exhaled NO. The change in exhaled NO was also compared to change in standard asthma outcome measures, asthma symptoms and spirometry.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Diagnostic
Asthma
Device: The Aerocrine NIOX MINO® Airway Inflammation Monitor
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
151
July 2007
June 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Children, and adults.
  • A history of physician-diagnosed asthma or asthma diagnosed by a physician.
  • Spirometry performed parameters.
  • An increased FENO value.
  • Symptomatic asthma as defined on the Asthma Control Questionnaire® (ACQ).

Exclusion Criteria:

  • Use of oral corticosteroids.
  • Use of intranasal corticosteroids.
  • Use of non-steroidal anti-asthma drugs.
  • Current serious conditions and/or therapies that are confounding factors.
  • Pregnancy.
  • Other significant respiratory diseases and/or cardiovascular diseases.
  • Current participation in another interventional clinical study.
  • Inability to comply with the study procedures, e.g. spirometry and FENO measurements according to standard procedures.
  • Unwillingness to sign informed consent and comply with treatment and visits.
  • Smoking within 6 months before the study, or a smoking history of >10 pack years or an equivalent amount of other tobacco use.
  • Known alcohol or drug abuser.
  • Food and beverage (other than water) intake within 1 hour before first FENO measurement
  • Nicotine (including nicotine chewing gum, nicotine patch, snuff etc) use within 1 hour before first FENO measurement.
  • Strenuous exercise within 1 hour before first FENO measurement
Both
4 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Sweden,   United Kingdom
 
NCT00388570
AER-036
No
Aerocrine AB, Ulrika Stein Grive, Aerocrine AB
Aerocrine AB
Not Provided
Study Chair: David Price, Professor Dept of General Practice and Primary Care, University of Aberdeen
Study Chair: Sven-Erik Dahlén, Professor Unit for Experimental Asthma and Allergy Research Division of Physiology, The National Institute of Environmental Medicine Karolinska Institutet
Aerocrine AB
November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP